Refractory cytopenias: Clinical course according to bone marrow cytology and cellularity

A. Riccardi, M. Giordano, M. Girino, M. Cazzola, C. M. Montecucco, E. Cassano, M. Danova, G. Ucci, A. Castello, A. Coci, E. Ascari

Research output: Contribution to journalArticle

Abstract

One hundred and one patients with refractory cytopenia were reviewed for morphological classification (using bone marrow, BM, imprints for cytology and Jamshidi biopsies for BM cellularity) and clinical course. Final diagnoses were: moderate aplastic anemia (MAA), myelodysplastic syndromes (MDS) and hypoplastic acute leukemia (HAL). Ninety-two patients received high dose testosterone enanthate (TE) as first treatment (starting dose=7-10 mg/week i.m. for at least three months). Median survival was significantly longer in MAA than in MDS and in HAL. Among MDS patients, those with primary acquired sideroblastic (AISA) and refractory (RA) anemia had median survival similar to those with MAA, but distinctly longer (p=0.01) than patients with RA with an excess of blasts (RAEB), RAEB in transformation (RAEBtr) and chronic myelomonocytic leukemia (CMMoL). Acute leukemia (AL) developed more rarely (p

Original languageEnglish
Pages (from-to)153-163
Number of pages11
JournalBlut
Volume54
Issue number3
DOIs
Publication statusPublished - Mar 1987

    Fingerprint

Keywords

  • Androgen therapy
  • Bone marrow cellularity
  • FAB classification
  • Prognosis
  • Refractory cytopenias

ASJC Scopus subject areas

  • Hematology

Cite this

Riccardi, A., Giordano, M., Girino, M., Cazzola, M., Montecucco, C. M., Cassano, E., Danova, M., Ucci, G., Castello, A., Coci, A., & Ascari, E. (1987). Refractory cytopenias: Clinical course according to bone marrow cytology and cellularity. Blut, 54(3), 153-163. https://doi.org/10.1007/BF00320369